GlassScriptPhysician profile
Stoni Johnston
NPI 1174073381
$4,728.48
in general payments reported to CMS, 2019-2025
29 companies · $833 in 2025
The $833 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,485 · 2022: $605 · 2023: $1,269 · 2024: $536 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Travel and Lodging: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.32 |
| Travel and Lodging | $221.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $585.94 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $537.01 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $513.41 | 2021-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $333.88 | 2021-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $298.99 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.83 | 2021-2025 | Caplyta |
| Lundbeck LLC | $234.19 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $172.86 | 2021 | |
| Neurocrine Biosciences, INC. | $109.84 | 2022-2025 | Ingrezza |
| Eisai INC. | $84.77 | 2021-2022 | |
| Tris Pharma INC | $82.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $71.81 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $63.67 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $63.65 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $61.70 | 2023-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $46.25 | 2021-2025 | Austedo, Austedo Xr |
| Biogen, INC. | $44.03 | 2024-2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $41.48 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.47 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $38.50 | 2021-2024 | Xelstrym, Secuado |
| Corium, LLC | $35.13 | 2021 | |
| Indivior INC. | $29.15 | 2021 | |
| Neos Therapeutics, LP | $28.28 | 2021 | |
| Adlon Therapeutics L.P. | $20.32 | 2021 | |
| Sun Pharmaceutical Industries INC. | $20.02 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.87 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.96 | 2022 | |
| Lilly USA, LLC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stoni Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.